PL1613288T3 - Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy - Google Patents

Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy

Info

Publication number: PL1613288T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; receptor agonist; sugar alcohol; solid pharmaceutical; solid
Prior art date: 2003-04-08

Application number

PL04725895T

Other languages

English (en)

Inventor

Tomoyuki Oomura

Madhusudhan Pudipeddi

Alan Edward Royce

Colleen Ruegger

Masaki Sasaki

Tokuhiro Tamura

Original Assignee

Novartis Ag

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2004-04-06

Publication date

2009-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1613288(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-06 Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag

2009-07-31 Publication of PL1613288T3 publication Critical patent/PL1613288T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PL04725895T 2003-04-08 2004-04-06 Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy PL1613288T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en)	2003-04-08	2004-04-06	Organic compounds
EP04725895A EP1613288B1 (en)	2003-04-08	2004-04-06	Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol

Publications (1)

Publication Number	Publication Date
PL1613288T3 true PL1613288T3 (pl)	2009-07-31

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10184951.1T PL2316431T3 (pl)	2003-04-08	2004-04-06	Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy
PL04725895T PL1613288T3 (pl)	2003-04-08	2004-04-06	Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL10184951.1T PL2316431T3 (pl)	2003-04-08	2004-04-06	Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy

Country Status (42)

Country	Link
US (11)	US20060275357A1 (pl)
EP (5)	EP2319502A1 (pl)
JP (3)	JP5495467B2 (pl)
KR (3)	KR101367574B1 (pl)
CN (2)	CN1767819B (pl)
AR (3)	AR043987A1 (pl)
AT (3)	AT501681B1 (pl)
AU (1)	AU2004228929B2 (pl)
BE (2)	BE1015972A5 (pl)
BR (1)	BRPI0409250B8 (pl)
CA (2)	CA2521325C (pl)
CL (2)	CL2004000745A1 (pl)
CY (3)	CY1110260T1 (pl)
DE (4)	DE602004017847D1 (pl)
DK (2)	DK1613288T3 (pl)
EC (1)	ECSP056090A (pl)
ES (3)	ES2228282B1 (pl)
FR (2)	FR2854073B1 (pl)
GB (1)	GB2400318B (pl)
GR (1)	GR1005052B (pl)
HK (3)	HK1071685A1 (pl)
HR (3)	HRP20050886B1 (pl)
HU (2)	HUE028247T2 (pl)
IL (3)	IL170888A (pl)
IS (2)	IS2682B (pl)
IT (1)	ITMI20040682A1 (pl)
LU (1)	LU91867I2 (pl)
MA (1)	MA27729A1 (pl)
MX (1)	MXPA05010860A (pl)
MY (1)	MY141249A (pl)
NO (4)	NO329332B1 (pl)
NZ (3)	NZ592339A (pl)
PE (5)	PE20150676A1 (pl)
PL (2)	PL2316431T3 (pl)
PT (1)	PT1613288E (pl)
RU (5)	RU2358716C2 (pl)
SG (1)	SG175449A1 (pl)
SI (2)	SI2316431T1 (pl)
TN (1)	TNSN05256A1 (pl)
TW (1)	TWI332847B (pl)
WO (1)	WO2004089341A1 (pl)
ZA (1)	ZA200507394B (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080096972A1 (en) *	2004-07-30	2008-04-24	Thitiwan Buranachokpaisan	Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
ES2357426T3 (es) *	2005-09-09	2011-04-26	Novartis Ag	Tratamiento de enfermedades autoinmunes.
NZ595196A (en)	2005-11-09	2013-03-28	Proteolix Inc	Peptide-based compounds for enzyme inhibition
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL2041158T3 (pl)	2006-06-19	2013-08-30	Onyx Therapeutics Inc	Peptydowe epoksyketony do hamowania proteasomu
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
KR102044064B1 (ko) *	2006-09-26	2019-11-12	노파르티스 아게	Ｓ１ｐ 조정제를 포함하는 제약 조성물
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) *	2006-09-26	2008-04-02	Novartis AG	Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) *	2007-02-14	2008-10-16	Emory University	Methods and compositions for treating or preventing infection using leukocyte sequestration agents
HUE035990T2 (en)	2007-03-29	2018-05-28	Daiichi Sankyo Co Ltd	Pharmaceutical preparation
PL2207791T5 (pl)	2007-10-04	2020-07-27	Onyx Therapeutics, Inc.	Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
KR101600098B1 (ko) *	2007-10-12	2016-03-04	노파르티스 아게	스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en)	2008-02-07	2013-07-02	Kyorin Pharmaceutical Co., Ltd.	Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
AU2009227629B2 (en)	2008-03-17	2014-09-04	Actelion Pharmaceuticals Ltd	Dosing regimen for a selective S1P1 receptor agonist
EP2303250A1 (en)	2008-06-20	2011-04-06	Novartis AG	Paediatric compositions for treating1 multiple sclerosis
RU2519768C2 (ru) *	2008-06-20	2014-06-20	Мерк Патент Гмбх	Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CA2735037C (en) *	2008-09-04	2016-07-12	Cargill Incorporated	Tabletting of erythritol
AP2011005690A0 (en)	2008-10-21	2011-06-30	Onyx Therapeutics Inc	Combination therapy with peptide epoxyketones.
BRPI0921533A2 (pt)	2008-11-11	2016-01-12	Novartis Ag	composto orgânicos
ES2643161T3 (es) *	2008-11-11	2017-11-21	Novartis Ag	Formas cristalinas de HCL de fingolimod
AU2013100531B4 (en) *	2008-11-11	2013-11-28	Novartis Ag	Crystalline forms of fingolimod HCL
CN102256984B (zh)	2008-12-17	2014-09-03	第一三共株式会社	制备二胺衍生物的方法
WO2010082531A1 (ja)	2009-01-13	2010-07-22	第一三共株式会社	活性化血液凝固因子阻害剤
ES2542236T3 (es)	2009-03-10	2015-08-03	Daiichi Sankyo Company, Limited	Procedimiento de producción de un derivado de diamina
CN102348680B (zh)	2009-03-13	2014-11-05	第一三共株式会社	用于制备光学活性二胺衍生物的方法
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
BRPI1011804A2 (pt) *	2009-06-18	2018-02-27	Daiichi Sankyo Company, Limited	composição farmacêutica com solubilidade melhorada
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja)	2009-11-13	2016-05-18	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	転移抑制のためのペプチドエポキシケトンの使用
BR112012022060A2 (pt)	2010-03-01	2018-05-08	Onyx Therapeutics Inc	composto para a inibição de imunoproteassoma
CN102791719B (zh)	2010-03-19	2015-07-29	第一三共株式会社	二胺衍生物的晶体及其制备方法
WO2011115067A1 (ja)	2010-03-19	2011-09-22	第一三共株式会社	抗凝固剤の溶出改善方法
CA2797029A1 (en) *	2010-04-22	2011-10-27	Ratiopharm Gmbh	A method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (ko)	2010-07-02	2017-12-01	다이이찌 산쿄 가부시키가이샤	광학 활성 디아민 유도체의 염의 제조 방법
US9266816B2 (en)	2010-11-25	2016-02-23	Shilpa Medicare Limited	Fingolimod polymorphs and their processes
WO2012100043A2 (en)	2011-01-19	2012-07-26	Pathlogica LLC	Controlled release oral pharmaceutical dosage forms comprising mgbg
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013019872A1 (en)	2011-08-01	2013-02-07	Teva Pharmaceutical Industries Ltd.	Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko)	2011-08-10	2019-01-21	다이이찌 산쿄 가부시키가이샤	디아민 유도체 함유 의약 조성물
WO2013091704A1 (en)	2011-12-22	2013-06-27	Synthon Bv	Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja)	2012-07-09	2015-08-24	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2859553T3 (es)	2013-01-08	2021-10-04	Pathologica Llc	Mitoguazona para el tratamiento de esclerosis múltiple progresiva
WO2014141298A2 (en) *	2013-03-11	2014-09-18	Astron Research Limited	Stable pharmaceutical composition of fingolimod
JP6294872B2 (ja) *	2013-04-26	2018-03-14	国立大学法人京都大学	脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) *	2013-05-13	2019-12-04	Synthon Bv	Composición farmacéutica que comprende fingolimod.
EP3027174B1 (en)	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) *	2014-08-22	2016-02-25	Sunshine Lake Pharma Co., Ltd.	Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
CA2974375A1 (en) *	2015-01-20	2016-07-28	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) *	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
EP3419607B1 (en)	2017-03-29	2019-11-20	Deva Holding Anonim Sirketi	Stable formulations of fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) *	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja)	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en)	2020-07-16	2023-05-24	Harbins Ruhr Bioscience, Inc.	Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en)	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
DE122011100012I1 (de) *	1992-10-21	2011-10-20	Mitsubishi Tanabe Pharma Corp	2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DE69524962T4 (de)	1994-08-22	2003-08-28	Mitsubishi Pharma Corp., Osaka	Benzolderivate und deren medizinische verwendung
SK282225B6 (sk)	1995-12-28	2001-12-03	Welfide Corporation	Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
JP2002241272A (ja)	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
PT990440E (pt) *	1997-02-27	2009-02-05	Novartis Ag	Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
WO1998045249A1 (fr) *	1997-04-04	1998-10-15	Yoshitomi Pharmaceutical Industries, Ltd.	Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja) *	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) *	1999-07-12	2002-04-13	우에노 도시오	스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
NZ523554A (en)	2000-07-13	2004-12-24	Sankyo Co	Amino alcohol derivatives
AU2001285331B2 (en) *	2000-08-31	2006-04-06	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DE60208355T2 (de)	2001-03-26	2006-07-27	Novartis Ag	2-amino-propanol derivate
US7521192B2 (en)	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
US20040235794A1 (en)	2001-09-04	2004-11-25	Shinji Nakade	Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
JP4152884B2 (ja)	2001-09-27	2008-09-17	杏林製薬株式会社	ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
CN1329372C (zh)	2001-09-27	2007-08-01	杏林制药株式会社	二芳基硫醚衍生物及其加成盐和免疫抑制剂
US7479504B2 (en)	2002-01-18	2009-01-20	Merck & Co., Inc.	Edg receptor agonists
AU2003216054B2 (en)	2002-01-18	2007-01-04	Merck & Co., Inc.	Selective S1P1/Edg1 receptor agonists
AU2003214873A1 (en)	2002-01-18	2003-09-02	Ceretek Llc	Methods of treating conditions associated with an edg receptor
AU2003202994B2 (en)	2002-01-18	2007-11-22	Merck Sharp & Dohme Corp.	N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
EP1772145B1 (en) *	2004-07-16	2011-03-23	Kyorin Pharmaceutical Co., Ltd.	Method of effectively using medicine and method concerning prevention of side effect

2004
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko active IP Right Grant
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx unknown
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Application Discontinuation
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx unknown
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de active Pending
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Application Discontinuation
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en unknown
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en active Application Filing
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
2005
- 2005-03-31 HK HK05102715A patent/HK1071685A1/xx not_active IP Right Cessation
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2006
- 2006-07-06 HK HK06107621.6A patent/HK1091114A1/xx not_active IP Right Cessation
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-08 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2010-11-08 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-21 HK HK11109933.8A patent/HK1155647A1/xx not_active IP Right Cessation
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20220031609A1 (en)	2022-02-03
NO20055231L (no)	2006-01-09
PL2316431T3 (pl)	2016-09-30
EP2008650A3 (en)	2011-04-27
RU2009105403A (ru)	2010-08-27
US20200237690A1 (en)	2020-07-30
ES2228282B1 (es)	2006-02-16
FR11C0036I1 (fr)	2011-10-14
KR101367574B1 (ko)	2014-02-25
HRP20100601B1 (hr)	2016-12-02
EP1613288A1 (en)	2006-01-11
PE20050396A1 (es)	2005-07-05
NO20055231D0 (no)	2005-11-07
NO20131287L (no)	2006-01-09
BRPI0409250B1 (pt)	2017-07-11
BRPI0409250A (pt)	2006-03-28
PE20130200A1 (es)	2013-03-09
MY141249A (en)	2010-03-31
RU2475236C2 (ru)	2013-02-20
FR2854073B1 (fr)	2008-03-14
ES2228282A1 (es)	2005-04-01
AT504853A2 (de)	2008-08-15
RU2358716C2 (ru)	2009-06-20
GR20040100121A (el)	2004-12-17
AT501681A1 (de)	2006-10-15
US20090203798A1 (en)	2009-08-13
US20190175527A1 (en)	2019-06-13
AU2004228929A1 (en)	2004-10-21
DK1613288T3 (da)	2009-03-23
CA2521325A1 (en)	2004-10-21
US20060275357A1 (en)	2006-12-07
NO329332B1 (no)	2010-09-27
AU2004228929B2 (en)	2008-02-07
NO2011016I1 (no)	2011-09-19
MXPA05010860A (es)	2006-05-25
LU91867I9 (pl)	2019-01-03
US20140011885A1 (en)	2014-01-09
PT1613288E (pt)	2009-02-25
EP2769713A1 (en)	2014-08-27
CY1117071T1 (el)	2017-04-05
KR20050121712A (ko)	2005-12-27
FR11C0036I2 (fr)	2023-12-29
RU2012148593A (ru)	2014-05-20
IL170888A (en)	2010-06-16
PE20150676A1 (es)	2015-05-17
DE602004017847D1 (de)	2009-01-02
IE20040246A1 (en)	2004-12-15
GB2400318A (en)	2004-10-13
BRPI0409250B8 (pt)	2022-01-18
CL2004000745A1 (es)	2005-02-11
US20110105620A1 (en)	2011-05-05
EP2008650A2 (en)	2008-12-31
DE202004021680U1 (de)	2010-04-22
ITMI20040682A1 (it)	2004-07-06
CY2011013I2 (el)	2014-04-09
HRP20050886A2 (en)	2006-11-30
GB2400318B (en)	2005-08-10
CN1767819A (zh)	2006-05-03
BE2011C030I2 (pl)	2023-03-07
ZA200507394B (en)	2007-03-28
RU2010147000A (ru)	2012-08-10
US20130108675A1 (en)	2013-05-02
HK1091114A1 (en)	2007-01-12
HRP20100600A2 (hr)	2011-03-31
JP2011006461A (ja)	2011-01-13
SI2316431T1 (sl)	2016-04-29
PE20131352A1 (es)	2013-11-14
DE122011100047I1 (de)	2011-12-15
CN101797241B (zh)	2013-03-27
EP2316431A1 (en)	2011-05-04
HK1071685A1 (en)	2005-07-29
JP5543298B2 (ja)	2014-07-09
JP2004307506A (ja)	2004-11-04
CN1767819B (zh)	2010-07-28
HK1155647A1 (en)	2012-05-25
IS8114A (is)	2005-11-01
RU2475237C2 (ru)	2013-02-20
HUS1100016I1 (hu)	2016-08-29
CY1110260T1 (el)	2014-04-09
SI1613288T1 (sl)	2009-04-30
CN101797241A (zh)	2010-08-11
TNSN05256A1 (en)	2007-07-10
IL242037A0 (en)	2015-11-30
US20080311188A1 (en)	2008-12-18
TW200503784A (en)	2005-02-01
AR078781A2 (es)	2011-11-30
WO2004089341A1 (en)	2004-10-21
NO335120B1 (no)	2014-09-22
JP2013177404A (ja)	2013-09-09
NZ542622A (en)	2009-01-31
CA2707750A1 (en)	2004-10-21
MA27729A1 (fr)	2006-01-02
JP5495467B2 (ja)	2014-05-21
GB0407819D0 (en)	2004-05-12
DK2316431T3 (en)	2016-01-11
EP2316431B1 (en)	2015-09-30
RU2010146697A (ru)	2012-05-27
US8324283B2 (en)	2012-12-04
NO20100250L (no)	2006-01-09
AR078782A2 (es)	2011-11-30
ES2320767T3 (es)	2009-05-28
NO334116B1 (no)	2013-12-16
ECSP056090A (es)	2006-03-01
EP2319502A1 (en)	2011-05-11
HUE028247T2 (en)	2016-12-28
ES2556947T3 (es)	2016-01-21
KR20120101148A (ko)	2012-09-12
DE102004016947A1 (de)	2004-10-21
CA2521325C (en)	2010-09-14
US20140255497A1 (en)	2014-09-11
EP1613288B1 (en)	2008-11-19
IL197578A0 (en)	2011-07-31
TWI332847B (en)	2010-11-11
PE20090743A1 (es)	2009-07-17
RU2005134173A (ru)	2006-09-10
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
AT501681B1 (de)	2012-04-15
HRP20100601A2 (hr)	2011-03-31
HRP20050886B1 (en)	2011-01-31
GR1005052B (el)	2005-11-30
IL197578A (en)	2015-10-29
NZ592339A (en)	2012-09-28
NZ586280A (en)	2011-12-22
FR2854073A1 (fr)	2004-10-29
ATE414508T1 (de)	2008-12-15
IS8885A (is)	2010-02-25
LU91867I2 (fr)	2011-11-08
SG175449A1 (en)	2011-11-28
CY2011013I1 (el)	2014-04-09
IS2682B (is)	2010-10-15
NO2011016I2 (no)	2012-08-27
KR20110005320A (ko)	2011-01-17
AR043987A1 (es)	2005-08-17
US20170290787A1 (en)	2017-10-12

Publication	Publication Date	Title
HUS1100016I1 (hu)	2016-08-29	S1P receptor antagonistát és cukoralkoholt tartalmazó gyógyszerészeti kompozíció
IL177902A0 (en)	2006-12-31	Pharmaceutical compositions containing an interleukin-6 antagonist
IL175973A0 (en)	2006-10-05	Pharmaceutical compositions comprising lercanidipine
IL174909A0 (en)	2006-08-20	Pharmaceutical compositions containing an interleukin-6 antagonist
IL176122A0 (en)	2006-10-05	Pharmaceutical compositions containing an interleukin-6 antagonist
EP1729744A4 (en)	2012-10-31	PHARMACEUTICAL PREPARATIONS
IL173913A0 (en)	2006-07-05	A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug
ZA200605631B (en)	2010-01-27	Directly compressible pharmaceutical composition for the oral administration of CCI-779
GB0426301D0 (en)	2004-12-29	Pharmaceutical formulations
IL155810A0 (en)	2003-12-23	Nmda receptor agonist pharmaceutical compositions
IL191804A0 (en)	2008-12-29	Solid dispersion containing an active ingredient and tablets for oral administration containing the same
HK1069111A1 (en)	2005-05-13	Pharmaceutical composition comprising a 5ht1 receptor agonist.
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
EP1811967A4 (en)	2008-08-20	METHOD AND FORMULATIONS FOR PREPARING PHARMACEUTICAL COMPOSITIONS WITH BUPROPION
IL177826A0 (en)	2006-12-31	Oral matrix formulations comprising licarbazepine
PL1655026T3 (pl)	2010-01-29	Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
IL178296A0 (en)	2007-02-11	Pharmaceutical compositions containing a gaba?? receptor agonist
GB0423800D0 (en)	2004-12-01	New pharmaceutical formulations
GB0416397D0 (en)	2004-08-25	Pharmaceutical formulations
HK1105358A1 (en)	2008-02-15	Solid pharmaceutical formulation
AU2003280065A1 (en)	2004-06-15	Bupropion hydrochloride solid dosage forms
HK1094676A1 (en)	2007-04-04	Solid pharmaceutical preparation form
SI1347760T1 (en)	2005-10-31	Nmda receptor agonist pharmaceutical compositions
GB0408070D0 (en)	2004-05-12	Pharmaceutical formulations
GB0408076D0 (en)	2004-05-12	Pharmaceutical formulations